Nā ʻōkuhi no ka hoʻohana ʻana iā Glidiab MV

ʻO ka lāʻau lapaʻau no ka maʻi maʻi ʻole wale nō ka hoʻololi ʻana i ka meaʻai, akā i ka hoʻohana ʻana i nā lāʻau lapaʻau kūikawā.

Me ka maʻi ʻōpiopio 2, maʻamau ka poʻe i nā lāʻau lapaʻau e hoʻokō ai i nā pae glycemia maʻamau. ʻO kekahi lāʻau lapaʻau ʻo Glidiab MV.

ʻO ka ʻike nui, ka hoʻonohonoho ʻana a me ke ʻano o ka hoʻokuʻu

ʻO ka lāʻau lapaʻau ʻO Glidiab MV kekahi o derivatives o ka sulfonylurea (2 mau hanauna), no laila ke manaʻo nei e hoʻowalewale i nā cell beta i loaʻa i ka pancreas.

ʻO ka lāʻau lapaʻau i hana ʻia ma ka wahi i Moscow e ka hui lāʻau lapaʻau ʻo Akrikhin a ua manaʻo ʻia he analogue o nā papa hypoglycemic Diabeton MV, i hana ʻia ma Farani. Loaʻa i ka ʻākena kahi palapala kaukaʻi e hōʻike ʻia e kahi hoʻoiho i hoʻololi ʻia.

Loaʻa ka lāʻau lapaʻau i ke ʻano o nā papa i loaʻa ke aniani ʻoi. Ua like lākou me ke ʻano o nā cylinders flat. Loaʻa ka lāʻau lapaʻau i nā paʻi o 30 a 60 mau papa.

Hoʻohālikelike me ka MV Diabeton, kahi nona ka nui o 0,06 g, loaʻa iā Glidiab MV ka hapalua o ka hāmeʻa ikaika (0,03 g).

Kūkulu:

• ʻO Gliclazide ka mea nui;
• cellulose (microcrystalline);
• hydroxypropyl methylcellulose;
• magnesium stearate;
• Aerosil;

Ua kuhikuhi ʻia nā poʻe maʻi he nui ʻo Glidiab 80, nona ka huina olakino ʻole, ʻaʻohe 30 mg, akā he 80 mg ma kēlā me kēia papa.

Ka hana lāʻau lapaʻau

Hoʻopilikia ka māhele o Glidiab MV i ke kino penei:

• e hoʻolōʻihi i ka mea huna o ka insulin i hana ʻia ma ka pancreas;
• hoʻonui i ka naʻau maʻi i ka hormone i hana ʻia;
• hoʻemi i ka waʻa mai ka manawa o ka ʻai ʻana i ka meaʻai e hoʻokuʻu i ka insulin;
• ma lalo o ka hopena o kēia lāʻau lapaʻau, hoʻihoʻi ʻia ka hoʻokahe nui ʻana o ka inikini i ka manawa mua i hoʻohālikelike ʻia i nā sulfonylureas ʻē aʻe;
• hoʻomaikaʻi i ka microcirculation ma muli o ka hoʻopili ʻana o nā ʻāpana platelet, hoʻihoʻi hou o ka hāmeʻe o ka pā vascular, a me ka hoʻohaʻahaʻa haʻahaʻa o ka microthrombosis;
• hoʻemi i ka glycemia;
• komo i ka hoʻopau ʻana o ka protenuria;
• lohi i ka hoʻolālāʻana o retinopathy;
• komo i ka hoʻohaʻahaʻa ʻana, kau ʻia i ka meaʻai i kauoha ʻia.

Lapaʻau lāʻau

ʻO ke kaʻina o ka hoʻihoʻi ʻana, ka hoʻohele ʻia i loko o ke kino, ka hana metabolism a me ka hoʻopihapiha ʻana o nā mea i kū like penei:

1. Kapehu. ^ E Ha yM. Ua aneane piha ʻia ka lāʻau lapaʻau ma o ka digestive tract (gastrointestinal tract). Piʻi ʻia kona kukuna i ka plasma, a hiki i kona lōʻihi loa mai ke manawa o ka hoʻokele ʻana ma hope o 6 a 12 paha hola. ʻAʻole pili ʻia nā laka i ka nui o ke kahe mau ʻana. Pono ka lāʻau no 24 mau hola.
2. Kahele. ^ E Ha yM. Ke hoʻonohonoho nei me nā protein plasma a me nā ʻāpana lāʻau i hoʻonoho ʻia ma 95%.
3. Hāpai. ^ E Ha yM. Hana ʻia kēia hana i ka puʻuwai, hōʻailona ʻia e ka hoʻokumu ʻana o nā metabolites kūpono ʻole.
4. ʻAno hānau. ^ E Ha yM. Ke hele mai nei ka hana ma nā palu ma ke ʻano o nā metabolites, ʻoiai wale nō 1% o ka lāʻau lapaʻau me ka urine. ʻO ka hoʻopauʻana hapalua-ola o ka lāʻau lapaʻau e loaʻa ana i nā hola 16.

ʻAʻole loli i nā kaʻina lāʻau pharmacokinetic o nā lāʻau lapaʻau i nā mea maʻi kahiko.

Nā hōʻailona a me nā contraindications

ʻO nā papa Glidiab MV he mau huaʻomaʻo hypoglycemic, no laila, ua hoʻohana ʻia i ka hoʻōla ʻana o ka maʻi type 2, i nā wahi ʻē aʻe o ka hoʻohaʻahaʻa i ka glucose i hoʻihoʻi ʻole i ka hōʻailona.

ʻO nā kumumanaʻo ka lawe ʻana i ka lāʻau lapaʻau nā:

• ketoacidosis;
• hana koʻikoʻi kahi keiki;
• ʻAno maʻi type 1;
• coma (maʻi maʻi a i ʻole hyperosmolar);
• hana;
• nā hōʻeha
• ke kālai;
• hapai
• nā kūlana e hoʻoili ai i ka hypoglycemia (no ka laʻana, nā maʻi o kahi ʻano maʻi);
• leukopenia;
• pālahalā nui;
• hypersensitivity i nā mea i loko o ka hana o ka huahana;
• hana waiū.

Nā ʻōkuhi no ka hoʻohana a me nā ʻōlelo aʻoaʻo kūikawā

ʻO ka make ʻana o ka lāʻau lapaʻau e hilinaʻi ʻia i nā hiʻohiʻona o ke ʻano o ke ahulau a me kona mau ʻōhumu, no laila ke koho ʻia e ke kauka ponoʻī no kēlā me kēia maʻi.

I ka hoʻomaka ʻana o ka lawe ʻana i ka lāʻau lapaʻau, kahi pāʻālua o 30 mg a i ʻole 1 papa e kuhikuhi ʻia. Aia i ke kūlana o ka mea maʻi i ka wā o ka hōʻola, hiki ke hoʻonui ʻia i ka nui o ka waiwai ikaika i kēlā me kēia lā i 120 mg (nui loa).

Lawe ʻia nā papa papaʻaila i ka wā kakahiaka kakahiaka (ma hoʻokahi lā). Hōʻemi ka hoʻomaʻamaʻa ʻole i ke aniani (me ka mea hana mai 15 a 80 ml / min) ʻaʻole ia e hoʻoponopono ʻia.

I ka hoʻomaka ʻana o nā lāʻau lapaʻau a hiki i ke koho ʻana i ka ʻai kūpono pono, ʻike pinepine nā mea maʻi i ka hypoglycemia e hana i ka hana e koi ai i ka pane wikiwiki a i ʻole ka hoʻonui nui ʻana.

ʻAʻole hiki i nā wahine ke hoʻohana i ka lāʻau lapaʻau i ka manawa o ka hānau ʻana i kahi keiki, me ka ʻānai ʻana iā ia.

ʻO kahi hōʻeha koʻikoʻi o ka hanaʻino i ka pūpū a me nā palaka paha e pāpā i ka hoʻohana ʻana i ka lāʻau lapaʻau a hiki i nā mea liʻiliʻi loa.

Nā rula noi:

1. He mea makemake no ka hoʻokō ʻana i ka hopena o ka noi ke hahai ʻana i kahi meaʻaiʻai a me ka hana maʻalahi. I nā lāʻai i kēlā me kēia lā, pono nā mea momona i loko o kahi liʻiliʻi.
2. He mea pono ia e nānā ʻia ka glycemia ma mua a ma hope o ka ʻaina, i hiki ai ke hoʻoponopono ʻia ke kaupaʻa e pili ana i nā hualoaʻa.
3. No ka hana ʻana, a i ʻole ke decompensated diabetes, pono e pono ke loli i ka lāʻau me nā inikini insulin.
4. I mea e pale ai i ka loaʻa ʻana o ka hypoglycemia, me kahi hopena like ʻole disulfiram, ʻaʻole inu i ka wai inu.
5. Lā ʻae ʻia ke kaʻai ʻana i nā meaʻai, ke nānā ʻole i nā mea ʻai i ka manawa o ka pōloli.
6. Ma mua o ka hoʻoikaika kino paʻakikī, pono e hōʻemi ʻia ka ʻona.

ʻO ka ʻike pili i nā lāʻau lapaʻaka hypoglycemic i:

• kanaka i loko o ʻelemakule;
• nā mea maʻi e hiki ʻole ke ʻai i ka kaulike;
• nā kānaka me ke kino nāwaliwali;
• nā mea maʻi me ka maʻi e like me ka lawa o ka pituitary-adrenal.

Nā hopena ʻaoʻao a me ka overdose

Hiki i nā papa ʻaina ke hōʻeha i kēia mau hopena:

• e pili ana i ka pūnaehana endocrine - hypoglycemia me ke ʻano o ka manaʻo o ke poʻo, ka ʻōpū, ka nāwaliwali, ka manawa hopohopo, ka puʻupuʻu, nā haʻalulu, ka nalowale o ka ʻike, ʻike maka ʻole a me ka hoʻonohonoho ʻana o ka neʻe;
• mai ka ʻaoʻao o ka hāwili ʻana - ka dyspepsia, anorexia, nā pilikia hoʻi i ka ate;
• leukopenia, thrombocytopenia, anemia;
• kahi hōʻike kūloko (hāhai, ʻeha, a i ʻole urticaria).

Me kahi overdose o ka lāʻau, loaʻa ka hypoglycemia. No ka hoʻopau ʻana i kona mau ʻōuli, lawa ia e hoʻopau i kekahi mau palaka, i ʻike ʻia e ʻike ke kanaka. I kahi kūlana i hiki ʻole ai i ka mea maʻi ke ʻai i ka ʻai, pono kāna e hāʻawi ʻia i kahi momona glucose intravenous (40%) a i kahi intramuscular injox. Ma hope o ka hoʻi ʻana i ka maʻi me kahi maʻi maʻi, e pono ʻoe i kahi ʻōmole ʻē aʻe e pale ai i kahi emi ʻana o ka glucose.

Hoʻopili pū kekahi me nā lāʻau lapaʻau a me nā hōʻailona

Hiki i ka hoʻohana ʻana o nā lāʻau ʻē aʻe e hui pū me Glidiab MV e hoʻomaikaʻi a hoʻoemi paha i ka hopena hypoglycemic.

Hoʻohui hui ʻia me nā lāʻau lapaʻau e like me:

• ACE inhibitors;
• nā hui antifungal (fluconazole);
• Nā NSAID;
• antihistamines;
• Pākuʻi;
• anti-tuberculosis lāʻau;
• Salicylates;
• Pentoxifylline;
• Etanaol;
• nā mea kanu e pāpā ai i ka ʻili huna tubular.

Hoʻomaʻamaʻa ʻia ka hopena hypoglycemic i ka wā i hui pū ʻia me nā lāʻau lapaʻau penei:

• pāpale;
• diuretics thiazide;
• Furosemide;
• nā maʻi e mālama ai i ka hana thyroid;
• hoʻomākaukau ka lithium;
• nā mea estrogen;
• ʻo ke ʻano o ka ʻōpū o ka waha.

I waena o nā lāʻau lapaʻau e loaʻa ai ka hopena e like me nā papa Glidiab MV, ʻoi aku ka ʻōlelo maʻamau:

• Meglimide;
• Alarahi
• Hoʻololi;
• Clay;
• Glimepiride;
• ʻĀpiki;
• Glairie
• Glibenclamide;
• Kuiluna.